ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 127,31
-0,05%
Dow Jones
39 056,39
0,44%
DAX
18 528,88
0,22%
Brent Oil
83,85
0,35%
Bitcoin
61 235,43
0,08%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Akari Therapeutics PLC (AKTX)

  7. Akari Therapeutics PLC (AKTX) Actualités

AKTX

Akari Therapeutics (AKTX)

Akari Therapeutics PLC
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:AKTX
DateHeureSourceTitreSymboleSociété
07/05/202423h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKTXAkari Therapeutics PLC
15/03/202417h53PR Newswire (US)Kuehn Law Encourages VIVK, MINM, SDPI, and AKTX Investors to Contact Law FirmNASDAQ:AKTXAkari Therapeutics PLC
11/03/202422h25Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:AKTXAkari Therapeutics PLC
09/01/202423h25Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:AKTXAkari Therapeutics PLC
04/01/202418h34Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:AKTXAkari Therapeutics PLC
03/01/202402h06Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AKTXAkari Therapeutics PLC
01/12/202314h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AKTXAkari Therapeutics PLC
27/10/202322h15Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:AKTXAkari Therapeutics PLC
27/10/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:AKTXAkari Therapeutics PLC
20/10/202322h29Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:AKTXAkari Therapeutics PLC
20/10/202322h23Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:AKTXAkari Therapeutics PLC
12/10/202322h43Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:AKTXAkari Therapeutics PLC
07/06/202312h03Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:AKTXAkari Therapeutics PLC
06/06/202315h00Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AKTXAkari Therapeutics PLC
31/05/202323h08Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:AKTXAkari Therapeutics PLC
16/05/202322h05GlobeNewswire Inc.Aspira Women’s Health Names Torsten Hombeck as Chief Financial OfficerNASDAQ:AKTXAkari Therapeutics PLC
14/04/202322h07Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:AKTXAkari Therapeutics PLC
14/02/202322h14Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:AKTXAkari Therapeutics PLC
09/11/202222h13Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:AKTXAkari Therapeutics PLC
04/11/202222h01Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-1/a)NASDAQ:AKTXAkari Therapeutics PLC
12/10/202222h32Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-1)NASDAQ:AKTXAkari Therapeutics PLC
14/09/202218h20Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:AKTXAkari Therapeutics PLC
13/06/202213h00GlobeNewswire Inc.Akari Therapeutics Announces the Appointment of Accomplished Biotech Executive Melissa Bradford-Klug as Chief Operating Officer to Lead Business Development and Company Growth StrategiesNASDAQ:AKTXAkari Therapeutics PLC
19/05/202222h05GlobeNewswire Inc.Akari Therapeutics Presents Results from the CASCADE and CORONET Studies in COVID-19 at the American Thoracic Society (ATS) 2022 Annual MeetingNASDAQ:AKTXAkari Therapeutics PLC
16/05/202212h43Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:AKTXAkari Therapeutics PLC
16/05/202212h00GlobeNewswire Inc.Akari Therapeutics Reports Full Year 2021 Financial Results and Highlights Clinical ProgressNASDAQ:AKTXAkari Therapeutics PLC
11/05/202213h00GlobeNewswire Inc.Akari Therapeutics to Present Results from Compassionate Use of Nomacopan for COVID-19 (CORONET) and Identification of Clinical Deterioration Risk in COVID-19 (CASCADE) at the American Thoracic Society (ATS) 2022 Annual MeetingNASDAQ:AKTXAkari Therapeutics PLC
10/05/202213h00GlobeNewswire Inc.Akari Therapeutics Announces Publication of Phase II Data of Investigational Nomacopan for the Treatment of Bullous Pemphigoid (BP) in JAMA DermatologyNASDAQ:AKTXAkari Therapeutics PLC
09/05/202213h00GlobeNewswire Inc.Akari Presents Results from Two Preclinical Development Programs of Long-Acting PAS-Nomacopan in Geographic Atrophy (GA) Dry Age-Related Macular Degeneration and Nomacopan in Experimental Immune-Mediated Conjunctival Disease (EIC)NASDAQ:AKTXAkari Therapeutics PLC
29/04/202223h11Edgar (US Regulatory)Notification That Form 20-f Will Be Submitted Late (nt 20-f)NASDAQ:AKTXAkari Therapeutics PLC
 Showing the most relevant articles for your search:NASDAQ:AKTX

Dernières Valeurs Consultées

EU
VIV
Vivendi
NASDAQ
AMZN
Amazon.com
EU
HO
Thales
EU
BEL20
Bel 20
EU
GLE
Societe Generale
EU
SGO
Cie de SaintGobain
FTSE
UKX
FTSE 100
EU
CS
Axa
EU
PX1
CAC 40
SPI
SP500
S&P 500
EU
LR
Legrand
EU
BNP
BNP Paribas
NYSE
KO
Coca Cola
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés